Bioequivalence of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine the bioequivalence of the combination of
pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference
tablet administered as a single total dose of 720:240 mg in healthy adults.